Background: Overall survival (OS) in platinum-sensitive recurrent ovarian cancer (PSR OC) has been assessed in recent trials of platinum-based regimens and novel targeted agents. However, OS data are still limited for women with PSR OC in real-world settings.
Methods: We retrospectively reviewed a sample of medical records from 3 countries (United Kingdom [UK], Canada [CAN], Netherlands [NL]). Women determined to have serous PSR OC (progression-free interval of ≥ 6 months after 1st-line platinum completion) during 2009-2013 were selected. For pts receiving 2nd-line therapy (1st treatment for PSR OC), OS was assessed via Kaplan-Meier from 2nd-line start until death or last record for all regimens combined and for carboplatin + paclitaxel specifically. For pts not starting 2nd-line, OS was assessed from date of PSR OC determination.
Results: 421 pts were analyzed (n = 312 UK, 73 CAN, 36 NL; median age: 61, 60, 60 years; stage IV at presentation: 20%, 5%, 14%). The majority of pts (73%, 62%, 81%) received 2nd-line therapy, most commonly carboplatin + paclitaxel (31%, 40%, 62% of initiators). Median time to 2nd-line start was 1 month from relapse. OS estimates are provided in the table. Medians not reached and confidence limits not estimable noted by “-”.
Conclusions: In this review, median OS from PSR OC determination and from 2nd-line initiation was consistent with recent reports. In the UK, OS from 2nd-line carboplatin + paclitaxel (37 months) was similar to the 33 months reported in the CALYPSO trial. OS was longer, however, in CAN (52 months), indicating possible selection of a better prognostic group, evidenced by the smaller proportion of CAN pts presenting with stage IV disease. That at least 20% of pts did not receive 2nd-line therapy combined with shorter OS in these pts may highlight a need for better treatment options.